Under one in 10 people that would benefit from GLP-1 drugs including Wegovy can access them, caution the WHO as it releases its inaugural advice on the drugs.
With in excess of 1,000,000,000 people worldwide now obese, it is urging increased and just availability to these injectable treatments.
According to projections, in excess of 2,000,000,000 will be living with obesity by 2030 without intervention.
"The new guidance affirms that excess weight is a long-term condition that can be managed with comprehensive and continuous support," remarked its chief Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and distribution challenges are key obstacles to broad access to the injections that can help people shift considerable body mass, says the organization.
Weight-Loss Drug Shortage
Despite the current best projected scenario, the production of GLP-1 therapies would only suffice for approximately 100 million people – less than 10% of eligible patients, according to the WHO.
The guideline encourages nations and manufacturers to increase access, via approaches including voluntary licensing.
The intellectual property rights on the active ingredient – the core component of the drug Wegovy – is set to lapse in a number of countries in 2026.
How Obesity Jabs Function
GLP-1 drugs imitate a biological compound to slow digestion, suppress the appetite and enhance the sense of being full so users reduce food intake.
Patients commonly start to lose weight in the initial weeks of starting on the regular doses.
Evidence suggests people may regain a significant portion within a year of stopping the medication, when their normal appetite come back.
Being overweight or obese increases your chance for contracting health problems, like type 2 diabetes, heart disease, stroke, and certain cancers.
Excess weight affects people in all nations and was associated with millions of fatalities worldwide in 2024, as per the health agency.
